CY1111675T1 - Αντικαρκινικοι συνδυασμοι που περιεχουν εναν ανασταλτικο παραγοντα toy vegf και ιρινοτεκανη - Google Patents
Αντικαρκινικοι συνδυασμοι που περιεχουν εναν ανασταλτικο παραγοντα toy vegf και ιρινοτεκανηInfo
- Publication number
- CY1111675T1 CY1111675T1 CY20111100551T CY111100551T CY1111675T1 CY 1111675 T1 CY1111675 T1 CY 1111675T1 CY 20111100551 T CY20111100551 T CY 20111100551T CY 111100551 T CY111100551 T CY 111100551T CY 1111675 T1 CY1111675 T1 CY 1111675T1
- Authority
- CY
- Cyprus
- Prior art keywords
- irinotecan
- vegf
- inhibitor
- toy
- combinations containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Αντικαρκινικοί συνδυασμοί που αποτελούνται από έναν αναστολέα VEGF και οι οποίοι συνδέονται με την ιρινοτεκάνη και είναι θεραπευτικά ωφέλιμοι στη θεραπεία των νεοπλαστικών ασθενειών.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0704868A FR2918279B1 (fr) | 2007-07-05 | 2007-07-05 | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
EP08827826A EP2173349B1 (fr) | 2007-07-05 | 2008-07-02 | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1111675T1 true CY1111675T1 (el) | 2015-10-07 |
Family
ID=38961256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100551T CY1111675T1 (el) | 2007-07-05 | 2011-06-08 | Αντικαρκινικοι συνδυασμοι που περιεχουν εναν ανασταλτικο παραγοντα toy vegf και ιρινοτεκανη |
Country Status (24)
Country | Link |
---|---|
US (3) | US20100160233A1 (el) |
EP (1) | EP2173349B1 (el) |
JP (4) | JP2010532335A (el) |
KR (4) | KR20150048910A (el) |
CN (3) | CN105833244A (el) |
AR (1) | AR067420A1 (el) |
AT (1) | ATE500829T1 (el) |
AU (1) | AU2008290442B2 (el) |
BR (1) | BRPI0812835B8 (el) |
CA (1) | CA2693152C (el) |
CY (1) | CY1111675T1 (el) |
DE (1) | DE602008005457D1 (el) |
DK (1) | DK2173349T3 (el) |
ES (1) | ES2362637T3 (el) |
FR (1) | FR2918279B1 (el) |
HR (1) | HRP20110432T1 (el) |
IL (2) | IL203132A (el) |
MX (1) | MX2009013950A (el) |
PL (1) | PL2173349T3 (el) |
PT (1) | PT2173349E (el) |
RS (1) | RS51777B (el) |
RU (1) | RU2471483C2 (el) |
SI (1) | SI2173349T1 (el) |
WO (1) | WO2009024667A2 (el) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1534340B1 (en) | 2002-09-06 | 2011-11-16 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto |
JP2010516625A (ja) | 2007-01-24 | 2010-05-20 | インサート セラピューティクス, インコーポレイテッド | 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート |
US20110223241A1 (en) * | 2008-10-16 | 2011-09-15 | Celator Pharmaceuticals, Inc. | Combination methods and compositions |
ES2354922B1 (es) | 2009-09-02 | 2012-02-07 | Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron | Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer. |
US20130029909A1 (en) * | 2009-09-15 | 2013-01-31 | John Ryan | Treatment of cancer |
KR20210030510A (ko) | 2011-01-13 | 2021-03-17 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
JO3283B1 (ar) * | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
TR201909951T4 (tr) | 2014-07-18 | 2019-07-22 | Sanofi Sa | Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem. |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0011407B8 (pt) * | 1999-06-08 | 2021-05-25 | Regeneron Pharma | molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão |
DE60314378T2 (de) * | 2002-03-01 | 2008-02-28 | Pfizer Italia S.R.L. | Kristalline polymorphe form von irinotecanhydrochlorid |
AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
JP2007501239A (ja) * | 2003-08-06 | 2007-01-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 放射線治療と組み合わせたvegfアンタゴニストの使用 |
CA2568534A1 (en) * | 2004-06-18 | 2006-01-26 | Regeneron Pharmaceuticals, Inc. | Vegf inhibitors for the treatment of malignant pleural effusion |
FR2878749B1 (fr) * | 2004-12-03 | 2007-12-21 | Aventis Pharma Sa | Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives |
-
2007
- 2007-07-05 FR FR0704868A patent/FR2918279B1/fr active Active
-
2008
- 2008-07-02 CN CN201610141168.3A patent/CN105833244A/zh active Pending
- 2008-07-02 KR KR1020157010064A patent/KR20150048910A/ko not_active Application Discontinuation
- 2008-07-02 AT AT08827826T patent/ATE500829T1/de active
- 2008-07-02 BR BRPI0812835A patent/BRPI0812835B8/pt active IP Right Grant
- 2008-07-02 PL PL08827826T patent/PL2173349T3/pl unknown
- 2008-07-02 DE DE602008005457T patent/DE602008005457D1/de active Active
- 2008-07-02 MX MX2009013950A patent/MX2009013950A/es active IP Right Grant
- 2008-07-02 CA CA2693152A patent/CA2693152C/fr not_active Expired - Fee Related
- 2008-07-02 RU RU2010103781/15A patent/RU2471483C2/ru active Protection Beyond IP Right Term
- 2008-07-02 AU AU2008290442A patent/AU2008290442B2/en active Active
- 2008-07-02 CN CN200880023537A patent/CN101686975A/zh active Pending
- 2008-07-02 ES ES08827826T patent/ES2362637T3/es active Active
- 2008-07-02 PT PT08827826T patent/PT2173349E/pt unknown
- 2008-07-02 CN CN201310556556.4A patent/CN103623392A/zh active Pending
- 2008-07-02 JP JP2010514042A patent/JP2010532335A/ja active Pending
- 2008-07-02 WO PCT/FR2008/000943 patent/WO2009024667A2/fr active Application Filing
- 2008-07-02 DK DK08827826.2T patent/DK2173349T3/da active
- 2008-07-02 RS RS20110215A patent/RS51777B/en unknown
- 2008-07-02 KR KR1020107000011A patent/KR20100031123A/ko not_active Application Discontinuation
- 2008-07-02 SI SI200830256T patent/SI2173349T1/sl unknown
- 2008-07-02 KR KR1020167017056A patent/KR20160079918A/ko not_active Application Discontinuation
- 2008-07-02 EP EP08827826A patent/EP2173349B1/fr active Active
- 2008-07-02 KR KR1020187026491A patent/KR20180105261A/ko not_active Application Discontinuation
- 2008-07-04 AR ARP080102894A patent/AR067420A1/es not_active Application Discontinuation
-
2010
- 2010-01-04 IL IL203132A patent/IL203132A/en active IP Right Grant
- 2010-01-04 US US12/651,767 patent/US20100160233A1/en not_active Abandoned
-
2011
- 2011-06-08 CY CY20111100551T patent/CY1111675T1/el unknown
- 2011-06-09 HR HR20110432T patent/HRP20110432T1/hr unknown
-
2014
- 2014-01-13 US US14/153,795 patent/US20140127202A1/en not_active Abandoned
- 2014-08-29 JP JP2014174963A patent/JP2014240422A/ja active Pending
-
2015
- 2015-08-31 IL IL240965A patent/IL240965A0/en unknown
-
2016
- 2016-11-16 JP JP2016222826A patent/JP2017052789A/ja active Pending
-
2018
- 2018-08-15 JP JP2018152805A patent/JP2019006785A/ja active Pending
-
2019
- 2019-02-11 US US16/272,315 patent/US20190275147A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111675T1 (el) | Αντικαρκινικοι συνδυασμοι που περιεχουν εναν ανασταλτικο παραγοντα toy vegf και ιρινοτεκανη | |
CY1121327T1 (el) | Τροποποιημενα αντισωματα anti-il-23p19 | |
CY1123883T1 (el) | Ανθρωποποιημενα αντισωματα κατα της liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου | |
CY1119070T1 (el) | Διαμορφωση της εκφρασης τρανσθυρετινης | |
CY1121046T1 (el) | Στοχευση toy abcb5 για θεραπεια του καρκινου | |
DK2185164T3 (da) | Sammensætning og terapeutisk antitumorvaccine | |
CY1122101T1 (el) | Τροποποιημενα πολυπεπτιδια ρελαξινης και χρησεις αυτων | |
DK1871341T3 (da) | Ladede lipoproteinkomplekser og deres anvendelse | |
CY2015013I1 (el) | Αντι-μολυσματικες πυραμιδινες και χρησεις αυτων | |
CY1113188T1 (el) | Τροποποιημενα fgf-21 πολυπεπτιδια και οι χρησεις τους | |
CY1115852T1 (el) | Φαρμακευτικες συνθεσεις | |
CY1114458T1 (el) | Πυρρολοβενζοδιαζεπινες και προϊοντα συζευξης αυτων | |
CY1115700T1 (el) | Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης | |
CR11299A (es) | Amidas heterociclicas utiles para el tratamiento de cancer y psoriasis | |
CY1115059T1 (el) | Θεραπευτικα απταμερη χρησιμα στην θεραπευτικη αγωγη διαταραχων σχετιζομενων με συμπληρωμα | |
CO6650372A2 (es) | Proteínas de unión de dominio variable dual que se unen a tnfy tweak, y métopdos para hacer y usar dichas proteínas | |
NO20084222L (no) | Målrettede bindende forbindelser rettet mot uPAR og deres anvendelse | |
DK2342233T3 (da) | Anti-CXCR4-antistoffer og anvendelse deraf i behandling af cancer | |
UY31484A1 (es) | Piperidinas heteroaril-sustituidas | |
BRPI0817293A2 (pt) | Derivado de benzoquinona e3330 em combinação com agentes quimioterapêuticos para o tratamento de câncer e angiogenese | |
DK2121989T3 (da) | K-ras-mutationer og anti-EGFR-antistofbehandling | |
DK3401327T3 (da) | Genprodukter med forskellig ekspression i tumorer og anvendelser deraf | |
BRPI0810905A2 (pt) | Integração das cadeias de propaganda e provisão de produto | |
DK2235002T3 (da) | 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer | |
DK2190991T3 (da) | SDF-1-Bindende nucleinsyrer og anvendelsen deraf |